Gensight Biologics SA, of Paris, said it completed a series B preferred stock financing of about $36 million. New investors include Fidelity Management & Research Co., Jennison Associates, Sphera Global Healthcare Fund, Perceptive Advisors and Healthcap. Existing series A investors also participated in the round.